New Drug Evaluation - Fluticasone furoate/umeclidinium bromide/vilanterol (Trelegy Ellipta®) for COPD

17th May 2018

The New Drug Evaluation for Fluticasone furoate/umeclidinium bromide/vilanterol (Trelegy Ellipta®) for the treatment of COPD is now online. This publication provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new product.

Visit our New Drug Evaluations page